Breaking News Instant updates and real-time market news.

KITE

Kite Pharma

$56.41

1.57 (2.86%)

, RHHBY

Roche

$30.83

0.13 (0.42%)

08:33
10/06/16
10/06
08:33
10/06/16
08:33

Kite Pharma initiates phase 1b/2 combination study for KTE-C19, atezolizumab

Kite Pharma (KITE) announced the first patient was enrolled in ZUMA-6, a Phase 1b/2 clinical study of KTE-C19 in combination with atezolizumab, Genentech's anti-PD-L1 cancer immunotherapy. The trial is designed to evaluate the safety and efficacy of the combination in patients with refractory diffuse large B-cell lymphoma. PD-L1 expression in DLBCL is associated with high-risk disease and poor outcomes. The interaction of PD-L1 and PD-1, which is expressed on KTE-C19, may dampen T-cell activity in some patients. As a result, use of the two compounds in combination could provide a synergistic effect since inhibiting PD-L1 with atezolizumab may enhance and prolong the activity and proliferation of KTE-C19. Kite entered a clinical collaboration in March 2016 with Genentech, a member of the Roche Group (RHHBY), to evaluate the safety and efficacy of KTE-C19 in combination with atezolizumab. The first ZUMA-6 patient was enrolled at the end of September 2016.

KITE

Kite Pharma

$56.41

1.57 (2.86%)

RHHBY

Roche

$30.83

0.13 (0.42%)

  • 07

    Oct

  • 18

    Oct

  • 19

    Oct

  • 06

    Nov

  • 10

    Nov

KITE Kite Pharma
$56.41

1.57 (2.86%)

09/27/16
RBCM
09/27/16
NO CHANGE
RBCM
Kite Pharma data positive, says RBC Capital
RBC Capital analyst Michael Yee says that Kite reported positive Phase II data for its KTE-C19 drug in DLBCL with a 47% complete response rate which beat expectations. The analyst says that the complete response rate "is very supportive of FDA approval." He keeps an Outperform rating on the shares.
09/27/16
COWN
09/27/16
NO CHANGE
COWN
Outperform
Efficacy of Kite's KTE-C19 'impressive,' safety 'acceptable,' says Cowen
Cowen analyst Eric Schmidt thinks the 33% complete remissions rate at three months in chemorefractory aggressive NHL patients in Kite Pharma's ZUMA-1 trial is "impressive" and that the safety experience in the trial is "acceptable." The two deaths reported in the trial need to be considered not only in the context of the treatment's efficacy but also in the context of the disease, said Schmidt, who continues to model KTE-C19 as a greater than $1B product and keeps an Outperform rating on Kite Pharma shares.
09/27/16
STFL
09/27/16
NO CHANGE
STFL
Kite Pharma data much better than standard of care, says Stifel
Stifel analyst Thomas Shrader says that Kite reported a complete response rate of 52% for its KTE-C19 drug in DLBCL, versus the standard of care's complete response rate of about 8%. The analyst says that the results exceed the level needed for FDA approval. He keeps a $74 price target and Buy rating on the shares.
09/27/16
LEER
09/27/16
NO CHANGE
LEER
Outperform
Kite's ZUMA-1 interim data incrementally positive for Juno, says Leerink
Leerink analyst Michael Schmidt says Kite Pharma's (KITE) top-line interim results from its pivotal ZUMA-1 trial of anti-CD19 CAR-T product KTE-C19 in patients with chemorefractory diffuse large B-cell lymphoma, or DLBCL, are incrementally positive for Juno Therapeutics (JUNO). While Juno is roughly one year behind Kite in DLBCL, the analyst believes its JCAR017 holds the promise to have a compelling safety/efficacy profile in lymphoma and Acute Lymphoblastic Leukemia. He reiterates an Outperform rating on Juno's shares.
RHHBY Roche
$30.83

0.13 (0.42%)

09/01/16
BMOC
09/01/16
NO CHANGE
BMOC
Bristol-Myers has negative read through from Roche data, says BMO Capital
BMO Capital analyst Alex Arfaei says that the positive data on Roche's (RHHBY) TECENTRIQ for second line NSCLC is negative for Bristol-Myers' (BMY) cancer drug, Opdivo. The analyst does not think that TECENTRIQ's results will be superior to that of Opdivo, but he believes that Roche's drug appears to have "a significant" benefit in PD-L1 positive patients." He predicts that Roche's drug could take "meaningful market share, particularly outside of the U.S." The analyst keeps a Market Perform rating on Bristol-Myers.
09/07/16
09/07/16
NO CHANGE

BioLineRx partnering with Roche company in cancer therapy research
BioLineRx (BLRX) has entered into a collaboration with Genentech, a member of the Roche (RHHBY) Group, to support several Phase 1b studies investigating BioLineRx's BL-8040 in combination with Atezolizumab, Genentech's anti-PDL1 cancer immunotherapy, in multiple cancer indications. The Phase 1b studies will evaluate the clinical response, safety and tolerability of the combination of these therapies, as well as multiple pharmacodynamic parameters, in hematologic malignancies and solid tumors. Under the agreement, Genentech will sponsor and conduct several Phase 1b trials in multiple solid cancer indications. In addition, BioLineRx will sponsor and conduct a Phase 1b study in acute myeloid leukemia patients. The studies are designed to evaluate the safety and efficacy of the combination of BL-8040 and Atezolizumab. Upon completion of the studies, both parties will have the option to expand the collaboration to include a pivotal registration study. Additional details of the collaboration were not disclosed.
09/12/16
JEFF
09/12/16
NO CHANGE
Target $57
JEFF
Hold
Jefferies cuts Bristol-Myers price target, upgrades AstraZeneca
Jefferies analyst Jeffrey Holford lowered his price target for Bristol-Myers Squibb (BMY) to $57 from $69 saying the stock is positioned for a "rough mid term ride." The analyst sees a "difficult catalyst" set for Bristol shares with "numerous" upcoming competitor read-outs in non-small cell lung cancer. The market could see worse than expected data from Bristol's CM-026 and CM-568 studies as well as better than expected data from AstraZeneca's (AZN) MYSTIC study and Roche's (RHHBY) Chemo-IO studies in the first half of 2017, Holford tells investors in a research note. He keeps a Hold rating on Bristol and upgraded this morning AstraZeneca to Buy from Hold. Holford prefers Astra for its immunology exposure.
09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.

TODAY'S FREE FLY STORIES

TGT

Target

$66.91

0.4 (0.60%)

, AZO

AutoZone

$740.85

8.1 (1.11%)

20:25
02/27/17
02/27
20:25
02/27/17
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

TGT

Target

$66.91

0.4 (0.60%)

AZO

AutoZone

$740.85

8.1 (1.11%)

DPZ

Domino's Pizza

$185.42

-0.86 (-0.46%)

VRX

Valeant

$16.71

0.53 (3.28%)

PAH

Platform Specialty Products

$13.30

0.25 (1.92%)

ENDP

Endo

$13.29

0.14 (1.06%)

DDD

3D Systems

$16.94

0.45 (2.73%)

SEAS

SeaWorld

$18.78

0.16 (0.86%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 28

    Feb

  • 28

    Feb

  • 28

    Feb

  • 28

    Feb

  • 28

    Feb

  • 28

    Feb

  • 28

    Feb

  • 28

    Feb

  • 02

    Mar

  • 13

    Mar

  • 14

    Mar

  • 14

    Mar

  • 19

    Mar

  • 22

    Mar

  • 23

    Mar

  • 24

    Mar

CSCO

Cisco

$34.26

-0.06 (-0.17%)

20:04
02/27/17
02/27
20:04
02/27/17
20:04
Hot Stocks
Cisco says signs three-year services agreement with Saudi Telecom »

At Mobile World Congress,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

  • 27

    Feb

  • 28

    Feb

  • 03

    Mar

YHOO

Yahoo

$45.71

0.16 (0.35%)

, VZ

Verizon

$49.94

-0.66 (-1.30%)

20:01
02/27/17
02/27
20:01
02/27/17
20:01
Hot Stocks
Yahoo responds to Senate information request on cybersecurity breaches »

Responding to a February…

YHOO

Yahoo

$45.71

0.16 (0.35%)

VZ

Verizon

$49.94

-0.66 (-1.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 06

    Mar

PCLN

Priceline

$1,632.01

0.39 (0.02%)

19:38
02/27/17
02/27
19:38
02/27/17
19:38
Hot Stocks
Priceline: 'Solid start' to Q1, shift of Easter into Q2 to pressure some metrics »

During the company's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

ROYT

Pacific Coast Oil

$1.94

0.02 (1.04%)

19:33
02/27/17
02/27
19:33
02/27/17
19:33
Downgrade
Pacific Coast Oil rating change  »

Pacific Coast Oil…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACAT

Arctic Cat

$18.49

-0.01 (-0.05%)

, BDRBF

Bombardier

$1.81

-0.03 (-1.63%)

19:28
02/27/17
02/27
19:28
02/27/17
19:28
Hot Stocks
Court rules in favor of Arctic Cat in Bombardier patent litigation »

Arctic Cat (ACAT)…

ACAT

Arctic Cat

$18.49

-0.01 (-0.05%)

BDRBF

Bombardier

$1.81

-0.03 (-1.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCLN

Priceline

$1,632.01

0.39 (0.02%)

19:17
02/27/17
02/27
19:17
02/27/17
19:17
Hot Stocks
Priceline CFO: 'Hopeful' on promised Trump tax reform »

During the company's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

PCLN

Priceline

$1,632.01

0.39 (0.02%)

19:16
02/27/17
02/27
19:16
02/27/17
19:16
Hot Stocks
Priceline says board approved new $2B buyback authorization »

Speaking during the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

VTVT

vTv Therapeutics

$6.14

0.45 (7.91%)

19:09
02/27/17
02/27
19:09
02/27/17
19:09
Hot Stocks
vTv Therapeutics sees reporting topline data from STEADFAST Part A in early 2018 »

Says STEADFAST Part B…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAC

AAC Holdings

$7.59

0.01 (0.13%)

18:55
02/27/17
02/27
18:55
02/27/17
18:55
Earnings
AAC Holdings sees FY17 adjusted EPS 50c-58c, consensus 72c »

Sees FY17 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

CSX

CSX

$48.71

0.23 (0.47%)

18:54
02/27/17
02/27
18:54
02/27/17
18:54
Hot Stocks
CSX sees at least $160M charge from 'management streamlining' plan »

CSX disclosed in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AWK

American Water

$76.45

0.15 (0.20%)

18:54
02/27/17
02/27
18:54
02/27/17
18:54
Hot Stocks
Iowa American Water rate adjustment approved by IUB »

Following a 10-month…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAC

AAC Holdings

$7.59

0.01 (0.13%)

18:53
02/27/17
02/27
18:53
02/27/17
18:53
Hot Stocks
AAC Holdings sees over $8M in savings in 2017 from workforce reduction »

Management said,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

MORN

Morningstar

$81.62

-0.1 (-0.12%)

18:52
02/27/17
02/27
18:52
02/27/17
18:52
Hot Stocks
Morningstar CFO Stephane Biehler to resign »

According to a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOC

Northrop Grumman

$248.60

3.55 (1.45%)

18:51
02/27/17
02/27
18:51
02/27/17
18:51
Hot Stocks
Northrop Grumman appoints Pamiljans as aerospace systems president »

The board of Northrop…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAC

AAC Holdings

$7.59

0.01 (0.13%)

18:51
02/27/17
02/27
18:51
02/27/17
18:51
Earnings
AAC Holdings reports Q4 adjusted EPS 15c, consensus 15c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

MS

Morgan Stanley

$45.84

0.31 (0.68%)

18:48
02/27/17
02/27
18:48
02/27/17
18:48
Hot Stocks
Morgan Stanley discloses erroneous client tax reporting, says in talks with IRS »

Morgan Stanley disclosed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 03

    Mar

MS

Morgan Stanley

$45.84

0.31 (0.68%)

, BK

BNY Mellon

$47.11

0.02 (0.04%)

18:47
02/27/17
02/27
18:47
02/27/17
18:47
Hot Stocks
Morgan Stanley says reached settlement in New York Mellon dispute »

Morgan Stanley (MS)…

MS

Morgan Stanley

$45.84

0.31 (0.68%)

BK

BNY Mellon

$47.11

0.02 (0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 03

    Mar

OLN

Olin Corp.

$30.90

0.1 (0.32%)

18:41
02/27/17
02/27
18:41
02/27/17
18:41
Hot Stocks
Olin Corp. chairman Joseph Rupp to retire »

Olin Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

  • 01

    Mar

  • 14

    Mar

WHLR

Wheeler REIT

$1.83

0.06 (3.39%)

18:35
02/27/17
02/27
18:35
02/27/17
18:35
Hot Stocks
Wheeler REIT revises dividend payment schedule »

Effective April 1, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

AHT

Ashford Hospitality

$6.80

0.39 (6.08%)

, FCH

Felcor Lodging

$7.33

0.25 (3.53%)

18:34
02/27/17
02/27
18:34
02/27/17
18:34
Hot Stocks
Ashford Hospitality: FelCor statements on proposal 'misguided and misleading' »

Ashford Hospitality Trust…

AHT

Ashford Hospitality

$6.80

0.39 (6.08%)

FCH

Felcor Lodging

$7.33

0.25 (3.53%)

AINC

Ashford

$56.72

-0.28 (-0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AHT

Ashford Hospitality

$6.80

0.39 (6.08%)

, FCH

Felcor Lodging

$7.33

0.25 (3.53%)

18:28
02/27/17
02/27
18:28
02/27/17
18:28
Hot Stocks
Ashford Hospitality Trust acknowledges Land and Buildings endorsement »

Ashford Hospitality Trust…

AHT

Ashford Hospitality

$6.80

0.39 (6.08%)

FCH

Felcor Lodging

$7.33

0.25 (3.53%)

AINC

Ashford

$56.72

-0.28 (-0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WHLR

Wheeler REIT

$1.83

0.06 (3.39%)

18:28
02/27/17
02/27
18:28
02/27/17
18:28
Hot Stocks
Wheeler REIT announces 1-for-8 reverse stock split »

The Company's Board…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

VTVT

vTv Therapeutics

$6.14

0.45 (7.91%)

18:18
02/27/17
02/27
18:18
02/27/17
18:18
Earnings
vTv Therapeutics reports Q4 EPS (42c), consensus (44c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DKL

Delek Logistics

$31.20

0.65 (2.13%)

18:10
02/27/17
02/27
18:10
02/27/17
18:10
Hot Stocks
Delek Logistics targets 10% annual increase in distribution through 2019 »

CEO Yemin concluded,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.